Linked Life Data

20415895

Source:http://linkedlifedata.com/resource/pubmed/id/20415895

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-4-26
pubmed:abstractText
The publication of the belatacept phase III studies offers a challenge in balancing benefits such as reduced burden of toxicity against risks such as EBV complications and more T cell mediated rejection.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1600-6143
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
441-2
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Belatacept: the promises and challenges of belatacept and costimulatory blockade.
pubmed:publicationType
Editorial, Comment